Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society Clinical Practice Guideline

Guideline OA: closed
📄 Open PDF View on PubMed View at publisher
⚙ AI-generated summary by qwen3.7-flash, 2026-09-01 ⓘ

This Endocrine Society guideline updates clinical practice recommendations for managing congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency, incorporating evidence and expert opinion on patient safety, quality of life, cost, and utilization.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

OBJECTIVE: To update the congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency clinical practice guideline published by the Endocrine Society in 2010. CONCLUSIONS: The writing committee presents updated best practice guidelines for the clinical management of congenital adrenal hyperplasia based on published evidence and expert opinion with added considerations for patient safety, quality of life, cost, and utilization.

My notes (saved in your browser only)

MeSH descriptors

Adrenal Hyperplasia, Congenital Endocrinology Societies, Medical Adrenal Hyperplasia, Congenital Adrenal Hyperplasia, Congenital Adrenal Hyperplasia, Congenital Adrenal Hyperplasia, Congenital Cost-Benefit Analysis Endocrinology Female Fetal Therapies Fetal Therapies Fetal Therapies Fetal Therapies Genetic Counseling Genetic Counseling Genetic Counseling Genetic Counseling Glucocorticoids Glucocorticoids

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-10-25T09:32:14.900964+00:00
pubmed
last seen: 2026-10-08T21:23:08.188623+00:00